Market news

Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...

Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...

Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.

Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.

Shares of Kodiak Sciences surged more than 170% Monday—on pace for its largest one-day increase on record—after the company announced its eye drug matched Regeneron's blockbuster Eylea in a Phase 3 trial. Palo Alto, Calif.-based Kodiak said that more than half of patients with wet age-related macul

Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.

Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.

Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' Eylea.

The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.

Tipranks Press Release.

Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch. Chris Fenimore, Regeneron’s executive vice

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron Pharmaceuticals has a market

Regeneron Pharmaceuticals (REGN) is back in focus after law firm Bronstein, Gewirtz & Grossman announced a securities class action tied to disclosures around the Phase III Fianlimab Libtayo trial. Recent trading tells a mixed story for Regeneron Pharmaceuticals. The share price is up 29.12% over the past 90 days and the 1 year total shareholder return is 39.33%, even though the 7 day share price return is down 4.11% as investors weigh the lawsuit headlines against a longer trend of positive...

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference. Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth

Harbor Funds, an investment management company, released its Q2 2026 investor letter for “Harbor Mid Cap Value Fund”. The letter can be downloaded here. Global equities experienced a sharp rally in Q2 2026, with the S&P 500 returning 15.2%, its strongest quarter since 2020, driven by a shift from software to hardware in the Artificial Intelligence […]

Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global complement inhibitors market is projected to increase fr

Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a...

Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare,...

The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of […]

Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease.

Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P 500’s […]

Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.

Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.

REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.